What your prescriber wants to see at a GLP‑1 visit.
A prescriber can do more with a clear history than with a number recalled at the door. The dose steps, the side effects that mattered and the direction of weight change are the facts that shape a GLP‑1 visit. The guidelines say how often to review them.
The dose history
The first thing a prescriber needs is the shape of the treatment: which medication, which dose, when it started and when it changed. A list of individual doses is less useful than a list of steps, because the step is the unit that connects a dose to a stretch of experience. “Eight weeks at 0.5 mg, then six weeks at 1 mg” tells the story in one line.
Within each step, the doses on time matter. A step with four missed doses is a different clinical picture from a step with none, even if the dose is the same. So does the form: a pen, a vial, a KwikPen or a tablet. A switch between forms can explain a change in technique, absorption or supply.
If the prescriber changed the dose at the last visit, bring the date and the old amount. If the change did not happen as planned, bring that too. The record is not a report card. It is the sequence of events the prescriber is trying to reconstruct.
The effects that mattered
Not every symptom needs a line. The ones that matter are the ones that changed your week: nausea that kept you from eating, constipation that lasted days, vomiting, severe abdominal pain, an injection-site reaction that spread, fatigue that altered your routine, hair shedding that started at a particular time. Note the date, the severity and how long it lasted.
Appetite and food noise are worth a line too, even though they are not adverse reactions in the label’s table. A prescriber may ask whether the appetite change has been steady, whether it fades before the next dose, or whether the noise has quieted. A simple three-level record is easier to answer than a general impression.
The injection site belongs here as well. A rotating site log shows whether a reaction follows a particular site or a particular pen. It also shows whether the technique changed. Those details are hard to recall in an exam room and easy to keep in a log.
Leave out the daily commentary that does not change a decision. A page of “felt fine” entries can bury the week that did not. A prescriber is looking for signal: a new symptom, a change in severity, a pattern tied to a dose step. If everything is equally detailed, nothing stands out.
One exception is a symptom that is new or unusual, even if it seems minor. A persistent headache, a change in vision, a lump, a rash that spreads: these are worth a line because they are the things a prescriber may ask about. The log does not need to decide whether they are related. It needs to record that they happened.
Bring the dates of any other care too: a visit to another clinician, an urgent care trip, a new prescription. A GLP‑1 visit does not happen in isolation, and a prescriber who can see the whole month is less likely to attribute a symptom to the wrong cause. The log is a hub for those facts, not only for doses. A prescriber who sees the whole month can spend the visit on the decision instead of the reconstruction, which is better for both people in the room and for the plan that comes out of the appointment and goes straight into the record. That is the whole goal of the page.
The trend, not the number
Weight is more useful as a direction than as a single reading. A 7‑day average, read beside the dose steps, shows whether the trend changed when the dose changed. A prescriber can see a flat step, a steady decline or a rise without treating one morning’s fluctuation as a signal.
The ADA’s Standards of Care for 2026 recommend monitoring obesity-related anthropometric measurements at least annually to inform treatment considerations, and increasing monitoring to at least every 3 months during active weight management treatment. The guideline sets a monitoring interval, not a daily weighing rule. A log that presents the trend without commentary fits that approach better than a page of daily numbers.
If you track waist or another measurement, bring it in the same form each time. A changing method looks like a changing body. The trend is only as good as the consistency behind it.
The questions and the plan
A prescriber cannot answer a question that was not asked. Bring the questions in writing, with the date and the step they refer to. “The nausea was worse in the first week of this step and then stopped; is that the pattern you expect?” is a better question than “is nausea normal?” “I missed a dose on the 12th and followed the label; do you want anything different next time?” is better than “what if I miss one?”
At the end of the visit, write down the plan in one sentence: what changes, when, and what to do if something goes wrong. If the plan is “no change,” write that too. The next visit starts from it, and the log reflects it from the same day.
Max HP prints the dose steps, doses on time, side‑effect days and weight trend on one page, which is the version a prescriber can scan in the room. The full log stays available if a question goes deeper. The app does not decide what the prescriber will want. It keeps the facts close enough to answer.
Questions
- What does a prescriber need to know at a GLP‑1 visit?
- The dose history by step, the doses that were missed, the side effects that mattered, the weight trend and the questions you want to ask. A one‑page summary covers most of it.
- How much detail is too much?
- If a detail changed your week or your routine, it belongs. If it is a daily score with no context, it can stay out. The goal is a history a prescriber can scan, not a complete diary.
- Do I bring my phone or a printout?
- Either can work. A printout is easy to hand over and annotate; a phone is easier to search. Bring the one‑page summary in the form you can explain, and keep the full log as backup.
- What if my prescriber does not ask for a log?
- Offer the one‑page summary at the start of the visit. A short, organized history is easier to use than a long narrative. If the prescriber prefers a different format, follow their lead.
Sources
- American Diabetes Association, “Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes—2026,” Diabetes Care 49, Supplement 1 (2026): S166–S182. Read 4 November 2026.
- Ozempic® (semaglutide) prescribing information, DailyMed. Revised May 2026. Read 3 November 2026.
- Wegovy® (semaglutide) prescribing information, DailyMed. Revised June 2026. Read 3 November 2026.
- Zepbound® (tirzepatide) prescribing information, DailyMed. Revised August 2026. Read 3 November 2026.